Skip to main content
Explore URMC

menu

Lung Cancer: Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Research Question:
Will the addition of cetuximab to the usual afatinib help to shrink tumors? Will the aide effects be better or worse with the combination?

Basic Study Information

Purpose:
If you are in Group 1, you will receive the study drugs afatinib and cetuximab. The combination of the two drugs is considered investigational. Once every two weeks you will receive cetuximab which will be given into a vein. Before receiving cetuximab, you will receive diphenhydramine hydrochloride (Benadryl) to help prevent a hypersensitivity reaction. You will also take one afatinib tablet every day. Afatinib is to be taken by mouth on an empty stomach (at least one hour before eating or two hours after a meal). Every 28 days is considered a "cycle." If you are in Group 2, you will receive afatinib alone. You will take one afatinib tablet every day. Afatinib is to be taken by mouth on an empty stomach (at least one hour before eating or two hours after a meal). Every 28 days is considered a "cycle."

Location: cancer center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02438722?term=S1403&rank=1
Study Reference #: CLUN-16119

Lead Researcher (Principal Investigator)

Lead Researcher: Megan Baumgart

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@urmc.rochester.edu

Additional Study Details

Return to Search